Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

MTEM

Molecular Templates Inc

Oct 14 • 04:00PM ET

0.3899

Dollar change -1.0801
Percentage change -73.48	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.70	Insider Own	17.39%	Shs Outstand	6.58M	Perf Week	-72.92%
Market Cap	2.57M	Forward P/E	-	EPS next Y	-2.35	Insider Trans	0.00%	Shs Float	5.44M	Perf Month	-67.24%
Income	-15.63M	PEG	-	EPS next Q	-1.03	Inst Own	42.69%	Short Float	2.61%	Perf Quarter	-71.95%
Sales	25.47M	P/S	0.10	EPS this Y	-62.78%	Inst Trans	3.83%	Short Ratio	2.31	Perf Half Y	-78.10%
Book/sh	1.08	P/B	0.36	EPS next Y	19.80%	ROA	-50.24%	Short Interest	0.14M	Perf Year	-94.20%
Cash/sh	1.47	P/C	0.27	EPS next 5Y	3.20%	ROE	-929.14%	52W Range	1.00 - 6.85	Perf YTD	-89.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	34.83%	ROI	-100.81%	52W High	-94.31%	Beta	1.13
Dividend TTM	-	Quick Ratio	1.56	Sales past 5Y	59.75%	Gross Margin	80.33%	52W Low	-61.01%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	1.56	EPS Y/Y TTM	78.46%	Oper. Margin	-74.02%	RSI (14)	19.84	Volatility	11.69% 8.40%
Employees	62	Debt/Eq	1.55	Sales Y/Y TTM	-49.41%	Profit Margin	-61.35%	Recom	1.00	Target Price	18.00
Option/Short	No / Yes	LT Debt/Eq	1.18	EPS Q/Q	57.32%	Payout	-	Rel Volume	114.07	Prev Close	1.47
Sales Surprise	33.02%	EPS Surprise	14.58%	Sales Q/Q	-91.67%	Earnings	Aug 14 AMC	Avg Volume	61.47K	Price	0.39
SMA20	-70.75%	SMA50	-71.95%	SMA200	-80.92%	Trades		Volume	7,011,065	Change	-73.48%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-21-21	Initiated	BofA Securities	Buy	$12
Feb-01-21	Initiated	UBS	Neutral	$13
Sep-08-20	Initiated	Jefferies	Buy	$21
Mar-25-20	Initiated	Stifel	Buy	$19
Feb-27-20	Initiated	Barclays	Overweight	$22
Apr-29-19	Initiated	UBS	Buy	$12
Dec-11-18	Initiated	Oppenheimer	Outperform	$15
Oct-08-18	Initiated	Laidlaw	Buy	$18

Aug-14-24 04:21PM	Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update (GlobeNewswire) -6.24%
Jun-21-24 07:30AM	7 F-Rated Penny Stocks to Avoid This June (InvestorPlace) -8.40%
Jun-03-24 08:11AM	Molecular Templates, Inc. Provides Interim Update (GlobeNewswire) +10.66%
May-30-24 07:47AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +5.17%
May-15-24 11:53PM	MTEM Stock Earnings: Molecular Templates Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:11PM	Loading…
05:11PM	Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-11-24 01:52PM	MTEM Stock Earnings: Molecular Templates Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Apr-09-24 08:11AM	Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism (GlobeNewswire) -6.57%
Mar-29-24 08:21AM	Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Mar-28-24 08:11AM	Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement (GlobeNewswire) -5.08%
Mar-04-24 08:11AM	Molecular Templates, Inc. Provides Interim Update (GlobeNewswire)
Feb-08-24 05:55PM	Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-13-23 04:11PM	Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Nov-02-23 04:11PM	Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors (GlobeNewswire)
Nov-01-23 04:12PM	Molecular Templates to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.09%
04:11PM	Loading…
Sep-28-23 04:11PM	Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer (GlobeNewswire)
Aug-25-23 08:50AM	Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM) (Zacks)
Aug-11-23 11:22AM	Molecular Templates Announces 1-for-15 Reverse Stock Split (GlobeNewswire)
Aug-10-23 08:08AM	Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Aug-04-23 09:16AM	After layoffs, Molecular Templates overhauls C-suite (American City Business Journals)
Aug-02-23 04:11PM	Molecular Templates Announces Executive Leadership Changes (GlobeNewswire)
Jul-20-23 06:55AM	Daily Vickers Top Buyers & Sellers for 07/20/2023 (Argus Research)
Jul-13-23 08:14AM	Molecular Templates Announces Up to $40 Million Private Placement Offering (GlobeNewswire) +8.51%
Jun-16-23 08:56PM	Molecular Templates Announces Debt Payoff and Restructuring (GlobeNewswire) +6.02%
Jun-01-23 07:57AM	Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma (GlobeNewswire)
May-26-23 05:10PM	Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-15-23 04:13PM	Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update (GlobeNewswire) +9.50%
May-04-23 10:00AM	Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know (Zacks) +8.86%
Apr-17-23 08:00AM	Improved Revenues Required Before Molecular Templates, Inc. (NASDAQ:MTEM) Stock's 45% Jump Looks Justified (Simply Wall St.)
Apr-07-23 06:50PM	Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169 (GlobeNewswire)
07:25PM	Loading…
Mar-30-23 07:25PM	Molecular Templates Inc. (MTEM) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +8.51%
06:10PM	Molecular Templates, Inc. Reports Fourth Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Mar-09-23 10:02AM	Molecular Templates Announces IND Acceptance by FDA for MT-8421 ETB Program Targeting CTLA-4 (GlobeNewswire) +5.98%
Mar-01-23 04:44PM	Molecular Templates Announces Participation in Upcoming Conferences (GlobeNewswire)
Dec-02-22 05:02PM	Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) and Participate at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -6.13%
Nov-23-22 04:30PM	Molecular Templates, Inc. to Present Fireside Chats at Two Upcoming Investor Conferences: Evercore ISIs 5th Annual HealthCONx Conference and Piper Sandlers 34th Annual Healthcare Conference (GlobeNewswire)
Nov-13-22 07:39AM	Molecular Templates Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-10-22 05:55PM	Molecular Templates Inc. (MTEM) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.16%
04:15PM	Molecular Templates, Inc. Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-04-22 11:00AM	Molecular Templates, Inc. to Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Aug-31-22 04:52PM	Molecular Templates Announces Participation in Four Upcoming Conferences (GlobeNewswire)
Aug-17-22 06:17AM	Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2022 (Simply Wall St.)
Aug-11-22 04:10PM	Molecular Templates, Inc. Reports Second Quarter 2022 Financial Results (GlobeNewswire) +6.64%
Aug-08-22 10:00AM	Field Trip Health Ltd. (FTRP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Aug-04-22 10:00AM	Molecular Templates Inc. (MTEM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jun-06-22 08:00AM	Molecular Templates Presentations at the 2022 ASCO Annual Meeting Demonstrate Advancement in PD-L1 and HER2 Programs (GlobeNewswire) -5.01%
May-17-22 04:05PM	Molecular Templates to Present at Upcoming Investor Conferences (GlobeNewswire) -6.84%
May-12-22 04:30PM	Molecular Templates, Inc. Reports First Quarter 2022 Financial Results (GlobeNewswire) +5.08%
May-10-22 05:25PM	Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates (Zacks) +8.21% -17.24%
May-06-22 10:18AM	Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt (Simply Wall St.) -8.23%
May-05-22 05:55PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.14%
03:00PM	Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-04-22 07:25AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings Meet Estimates (Zacks)
Apr-12-22 07:30AM	Molecular Templates Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach (GlobeNewswire)
Apr-08-22 08:00AM	Molecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid Tumors (GlobeNewswire) -5.18%
Mar-28-22 04:30PM	Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results (GlobeNewswire) +21.11%
Mar-18-22 12:39PM	Investors in Molecular Templates (NASDAQ:MTEM) have unfortunately lost 77% over the last year (Simply Wall St.)
Mar-02-22 08:00AM	Molecular Templates Strengthens Board of Directors and Management Team (GlobeNewswire)
Mar-01-22 08:00AM	Molecular Templates to Present at the Upcoming Investor Conferences (GlobeNewswire)
Jan-17-22 07:08AM	Is Molecular Templates, Inc. (NASDAQ:MTEM) Popular Amongst Institutions? (Simply Wall St.)
Nov-30-21 05:30PM	Molecular Templates Provides Corporate Update and Outlines 2022 Milestones (GlobeNewswire)
Nov-18-21 08:00AM	Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402 (GlobeNewswire) -5.08%
Nov-16-21 09:06AM	Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way? (Simply Wall St.) -7.06%
Nov-15-21 12:25PM	Molecular Templates Inc. (MTEM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results (GlobeNewswire)
Oct-28-21 03:05PM	Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
12:31PM	Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates (Zacks)
Oct-12-21 09:08AM	Wall Street Analysts Predict a 98% Upside in Molecular Templates Inc. (MTEM): Here's What You Should Know (Zacks)
Sep-22-21 03:24AM	Molecular Templates Inc. (MTEM) Moves 11.8% Higher: Will This Strength Last? (Zacks)
Sep-20-21 08:00AM	Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (GlobeNewswire)
Sep-14-21 12:09PM	2 Strong Buy Stocks Trading at Steep Discounts (TipRanks)
Aug-12-21 08:05PM	Molecular Templates Inc. (MTEM) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +9.99%
04:30PM	Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results (GlobeNewswire)
Aug-05-21 10:50AM	10 Best Biotech Stocks to Buy According to Alan Fraziers Frazier Healthcare Partners (Insider Monkey)
Jul-29-21 03:05PM	Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-21-21 03:20PM	Molecular Templates, Inc. (MTEM) Fell Out Of Favor With Hedge Funds? (Insider Monkey)
Jul-19-21 05:27AM	Here's What Molecular Templates, Inc.'s (NASDAQ:MTEM) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jul-09-21 08:00AM	Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors (GlobeNewswire)
Jul-06-21 08:00AM	Molecular Templates to Present at the Ladenburg Thalmann 2021 Healthcare Conference (GlobeNewswire)
Jun-30-21 08:30AM	Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors (GlobeNewswire)
May-18-21 03:04AM	Analysts Are More Bearish On Molecular Templates, Inc. (NASDAQ:MTEM) Than They Used To Be (Simply Wall St.)
May-13-21 07:50PM	Molecular Templates Inc. (MTEM) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -5.76%
04:30PM	Molecular Templates, Inc. Reports First Quarter 2021 Financial Results (GlobeNewswire)
Apr-20-21 11:36AM	Insider Buying Of Molecular Templates Stock Corresponds With Analyst Ratings (SmarterAnalyst)
Apr-12-21 07:00AM	Molecular Templates Announces Poster Presentations on its Engineered Toxin Bodies at the American Association of Cancer Research (AACR) Virtual Annual Meeting I (GlobeNewswire)
Apr-05-21 04:12PM	Why Molecular Templates Stock Crashed Today (Motley Fool) -23.55% -9.52%
11:48AM	Molecular Templates Stock Falls After It Stops MT-3724 Development In Hematological Malignancies (Benzinga)
07:00AM	Molecular Templates to Prioritize Next-Generation ETB Candidates (GlobeNewswire)
Mar-21-21 03:37AM	Upgrade: Analysts Just Made A Dazzling Increase To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts (Simply Wall St.)
Mar-18-21 04:30PM	Molecular Templates, Inc. Reports Fourth Quarter 2020 Financial Results (GlobeNewswire) +7.81%
Feb-26-21 08:00AM	Molecular Templates to Participate in Upcoming Virtual Investor Conferences (GlobeNewswire)
Feb-21-21 03:02AM	Newsflash: Molecular Templates, Inc. (NASDAQ:MTEM) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Feb-18-21 07:30AM	Molecular Templates, Inc. Announces Pricing of $75.9 Million Public Equity Offering (GlobeNewswire) -7.49%
Feb-17-21 04:05PM	Molecular Templates, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-11-21 09:13AM	Molecular Templates Shares Jump On Research Pact With Bristol-Myers In Cancer Settings (Benzinga) +8.74%
07:30AM	Molecular Templates Establishes Multi-Target Collaboration With Bristol Myers Squibb for the Discovery and Development of Next Generation Engineered Toxin Bodies for the Treatment of Cancer (GlobeNewswire)
Feb-08-21 06:20AM	Investors Who Bought Molecular Templates (NASDAQ:MTEM) Shares Three Years Ago Are Now Up 41% (Simply Wall St.)
Jan-19-21 08:00AM	Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology (GlobeNewswire) +6.70%
Dec-21-20 04:30PM	Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study (GlobeNewswire) +11.89%
Dec-18-20 10:21PM	Is MTEM A Good Stock To Buy Now According To Hedge Funds? (Insider Monkey)

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariepy, and Leigh Revers in 2001 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOTECH TARGET N V	10% Owner	Apr 02 '24	Buy	2.35	250,000	587,500	1,279,820	Apr 04 08:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MTEM

Molecular Templates Inc

Upgrade your FINVIZ experience